Biodesix (NASDAQ:BDSX) CEO Scott Hutton Sells 3,559 Shares

Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton sold 3,559 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total transaction of $35,874.72. Following the completion of the transaction, the chief executive officer directly owned 45,413 shares in the company, valued at approximately $457,763.04. This represents a 7.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Scott Hutton also recently made the following trade(s):

• On Friday, January 16th, Scott Hutton sold 970 shares of Biodesix stock. The shares were sold at an average price of $8.15, for a total transaction of $7,905.50.

Biodesix Price Performance

BDSX stock traded down $0.05 during mid-day trading on Wednesday, reaching $10.35. The company’s stock had a trading volume of 86,859 shares, compared to its average volume of 3,040,306. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. The company’s 50 day moving average is $8.30 and its two-hundred day moving average is $7.95. Biodesix, Inc. has a fifty-two week low of $3.44 and a fifty-two week high of $20.40. The stock has a market cap of $82.39 million, a PE ratio of -1.86 and a beta of 0.67.

Institutional Trading of Biodesix

A number of hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd lifted its position in Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after buying an additional 102,494 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Biodesix in the 3rd quarter valued at approximately $113,000. Oracle Investment Management Inc. acquired a new position in shares of Biodesix in the 3rd quarter worth approximately $113,000. Geode Capital Management LLC boosted its position in shares of Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after purchasing an additional 2,235 shares during the period. Finally, Aberdeen Group plc acquired a new stake in Biodesix in the 4th quarter valued at approximately $1,784,000. 20.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BDSX has been the topic of a number of recent research reports. Wall Street Zen raised Biodesix from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.50.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.